Natera stock trades at EUR 357.80 in weekend trading
Published on 10/10/2026 at 10:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKey points in brief
- Lang & Schwarz quoted Natera at EUR 357.80 in weekend trading on October 10, 2026.
- Natera and Alliance Foundation Trials announced a phase III breast cancer trial on October 5.
- Natera reported new Signatera data from ASTRO 2026 on October 6.
Market context: Market report S&P 500.
Lang & Schwarz quoted Natera at EUR 357.80 in weekend trading at 10:35 a.m. CEST on October 10, 2026, up EUR 0.50, or 0.14 percent, versus EUR 357.30, the close at Lang & Schwarz on October 9, 2026.
The week in figures
The latest Lang & Schwarz weekend price was EUR 357.80, compared with the EUR 357.30 close at Lang & Schwarz on October 9, 2026. The quote's bid was EUR 357.10 and its ask was EUR 358.50.
The further course of weekend trading at Lang & Schwarz until 1:00 p.m. CET/CEST is shown by the continuously updated real-time quote of Natera stock.
Chronology of the week
On October 5, Natera and Alliance Foundation Trials announced the launch of AFT-70 NAVIGATE, a randomized phase III trial for intermediate- and high-risk ER-positive/HER2-negative early breast cancer. AFT expects to enroll more than 2,000 patients at approximately 200 sites, according to Natera.
On October 6, Natera reported four oral presentations at the ASTRO 2026 Annual Meeting. In a real-world locally advanced rectal cancer study, Signatera identified every instance of local cancer growth or recurrence, with 100 percent sensitivity and 97 percent specificity, Natera said.
Dates of the coming week
The next Xetra session is scheduled for October 12, 2026. The reviewed company releases do not state a company event date for that session.
